相关实验视频
Updated: Jul 15, 2025

04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
501
碳氧甲基基托桑多巴胺联体:用于鼻内抗帕金森治疗的合成和评估
Sante Di Gioia1, Giuseppe Fracchiolla2, Stefania Cometa3
1Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
International journal of biological macromolecules
|October 2, 2023
概括
为帕金森病 (PD) 研究而合成了将多巴胺与碳甲基相关联的新型宏分子合物. 这些稳定,抗氧化合物显示出良好的细胞吸收和没有细胞毒性,表明潜在的治疗应用.
科学领域:
- 生物材料科学 生物材料科学
- 神经科学是一个神经科学.
- 药物运输 药物运输 药物运输
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病.
- 多巴胺 (DA) 是影响PD的关键神经递质.
- 开发新的PD药物输送系统至关重要.
研究的目的:
- 合成和描述多巴胺 (DA) 与N,O-碳素甲基 (N,O-CMCS) 和O-碳素甲基 (O-CMCS) 的两个新型宏分子合物.
- 为了评估这些DA-基托桑结合物的稳定性,释放动力学,自我组装特性,抗氧化活性和细胞兼容性,以对潜在的PD治疗应用进行评估.
主要方法:
- 无有机溶剂合成DA-奇托桑合物.
- 使用FT-IR,1H NMR,差分扫描热量测量 (DSC) 和热重力测量分析 (TGA) 的表征.
- 在模拟的鼻液中进行体外释放研究,传输电子显微镜 (TEM),光子相关谱 (PCS),DPPH激素清除试验,以及使用SH-SY5Y细胞的细胞相容性研究.
主要成果:
- 两种稳定的DA-基托桑合物已成功合成和表征.
- 在O-CMCS-DA结合体表现出更快的药物释放,由于减少了硬质障碍.
- 结合物表现出抗氧化活性,形成纳米颗粒,并在SH-SY5Y细胞中表现出良好的细胞相容性,具有显著的细胞吸收.
结论:
- 合成的DA-基托联合体是稳定的,具有抗氧化特性,适合形成纳米粒子.
- 这些新型生物材料由于其生物相容性和细胞吸收,显示出在帕金森病治疗中药物输送的前景.
相关概念视频
Parkinson's Disease: Treatment
292
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
292
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.2K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.2K
Cholinergic Antagonists: Pharmacokinetics
509
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
509
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
1.0K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.0K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
320
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
320

